Articles related to FDA

Ulotaront’s failure to meet its primary endpoint in recent phase 3 trials raises questions about the drug’s future and emphasizes the need for more effective treatments in the field of schizophrenia.

Discover how Exxua, the newly FDA-approved antidepressant, could be a game-changer in treating major depressive disorder, backed by robust clinical trials and a manageable side effect profile.

The FDA’s approval of brexpiprazole for Alzheimer’s-related agitation has sparked a debate over its efficacy and safety, raising concerns that extend beyond this specific drug to the integrity of the regulatory process itself.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.

The FDA’s recent approval of updated Pfizer-BioNTech and Moderna COVID-19 vaccines marks a significant step in adapting to current viral variants. Stay informed and prepare to update vaccination protocols accordingly.

Stay informed on the FDA’s new cybersecurity guidelines for medical devices, as they set the standard for compliance and patient data safety.